VOR news

Vor Biopharma's board adopted and stockholders approved an amended and restated 2021 Equity Incentive Plan on June 11, 2026, increasing the share reserve to 2.3 million shares plus annual 4% increases through 2035. The expanded plan enhances the company's ability to attract and retain talent through…

China's NMPA conditionally approved telitacicept for IgA nephropathy, marking the first BAFF/APRIL-targeting therapy approved for this indication and the fourth approval for the drug. The approval, based on positive Phase 3 TELIGAN results, validates the dual mechanism and supports Vor Bio's global …